Workflow
Champions Oncology(CSBR) - 2025 Q2 - Quarterly Results
CSBRChampions Oncology(CSBR)2024-12-11 21:40

Financial Performance - Total revenue for Q2 fiscal 2025 was 13.5million,a1713.5 million, a 17% increase from 11.6 million in Q2 fiscal 2024[7] - Adjusted EBITDA for Q2 fiscal 2025 was 1.1million,comparedtoanadjustedEBITDAlossof1.1 million, compared to an adjusted EBITDA loss of 1.4 million in Q2 fiscal 2024[8] - Gross profit for Q2 fiscal 2025 was 6.1million,withamarginof456.1 million, with a margin of 45%, up from a margin of 43% in Q2 fiscal 2024[9] - For the first half of fiscal 2025, total revenue increased 14.2% to 27.6 million compared to 24.1millioninthesameperiodlastyear[15]−Thecompanyprojectsrevenuegrowthfortheyearofatleast1024.1 million in the same period last year[15] - The company projects revenue growth for the year of at least 10% to 15%[6] - Oncology services revenue for the three months ended October 31, 2024, was 13.489 million, a 16.6% increase from 11.573millionforthesameperiodin2023[27]−NetincomeforthesixmonthsendedOctober31,2024,was11.573 million for the same period in 2023[27] - Net income for the six months ended October 31, 2024, was 2.041 million, compared to a net loss of 4.637millionforthesameperiodin2023[27]−Thecompanyreportedabasicnetincomepershareof4.637 million for the same period in 2023[27] - The company reported a basic net income per share of 0.05 for the three months ended October 31, 2024, compared to a loss of 0.15pershareforthesameperiodin2023[27]ExpensesandCosts−ResearchanddevelopmentexpensesforQ2fiscal2025decreasedby32.80.15 per share for the same period in 2023[27] Expenses and Costs - Research and development expenses for Q2 fiscal 2025 decreased by 32.8% to 1.7 million compared to 2.5millioninQ2fiscal2024[10]−TotalcostsandoperatingexpensesforQ2fiscal2025were2.5 million in Q2 fiscal 2024[10] - Total costs and operating expenses for Q2 fiscal 2025 were 12.8 million, a decrease of 5.7% from 13.5millioninQ2fiscal2024[7]−CostofoncologyservicesforQ2fiscal2025was13.5 million in Q2 fiscal 2024[7] - Cost of oncology services for Q2 fiscal 2025 was 7.4 million, an increase of 12.2% from 6.6millioninQ2fiscal2024[9]−ResearchanddevelopmentexpensesforthethreemonthsendedOctober31,2024,were6.6 million in Q2 fiscal 2024[9] - Research and development expenses for the three months ended October 31, 2024, were 1.689 million, down from 2.515millionforthesameperiodin2023[27]AssetsandLiabilities−Totalcurrentassetsincreasedto2.515 million for the same period in 2023[27] Assets and Liabilities - Total current assets increased to 14.084 million as of October 31, 2024, from 13.639millionasofApril30,2024[28]−Totalliabilitiesdecreasedto13.639 million as of April 30, 2024[28] - Total liabilities decreased to 24.559 million as of October 31, 2024, from 28.035millionasofApril30,2024[28]−Cashandcashequivalentsincreasedto28.035 million as of April 30, 2024[28] - Cash and cash equivalents increased to 2.754 million as of October 31, 2024, from 2.618millionasofApril30,2024[28]−Deferredrevenuedecreasedto2.618 million as of April 30, 2024[28] - Deferred revenue decreased to 10.220 million as of October 31, 2024, from 12.094millionasofApril30,2024[28]CashFlow−Thecompanyendedthequarterwithcashonhandofapproximately12.094 million as of April 30, 2024[28] Cash Flow - The company ended the quarter with cash on hand of approximately 2.8 million and no debt[14] - Net cash provided by operating activities for the six months ended October 31, 2024, was 28,comparedtoanetcashusedof28, compared to a net cash used of 3.402 million for the same period in 2023[29] Share Information - The weighted average common shares outstanding for the three months ended October 31, 2024, was 13,593,766, compared to 13,497,061 for the same period in 2023[27]